Quantoom Biosciences Signs MoU with Univercells and Fiocruz for Second-Generation RNA Technologies

• Quantoom Biosciences, Univercells, and Fiocruz signed an MoU to advance RNA-based vaccines and therapies.

• The agreement includes building an mRNA manufacturing facility in Brazil and developing second-generation saRNA technologies.

Quantoom Biosciences and Univercells have entered into a historic Memorandum of Understanding (MoU) with Brazil’s Fiocruz to enhance global health outcomes through RNA-based vaccines and therapies. The agreement was formalized during the Belgian Economic Mission to Brazil, with Her Royal Highness Princess Astrid of Belgium presiding over the signing ceremony.

The MoU marks a collaborative effort between the Brazilian Institute of Technology on Immunobiologicals (Bio-Manguinhos/Fiocruz) and the Belgian biotech companies. Key projects include the development of second-generation self-amplifying RNA (saRNA) vaccines and RNA-based cancer therapies. A new mRNA manufacturing facility is also planned for Brazil, designed to integrate local enzyme production to bolster regional biopharmaceutical autonomy.

Speaking on the occasion, José Castillo, CEO of Quantoom Biosciences, said: “This partnership highlights the transformative power of cross-border collaboration in addressing some of the world’s most pressing health challenges.”

The collaboration extends beyond RNA technology, encompassing “One Health” initiatives that connect human, animal, and environmental health. Additionally, the integration of Quantoom’s Ntensify mRNA production system at Bio-Manguinhos earlier this year lays the foundation for further technological advancements.

Hugues Bultot, CEO of Univercells, added: “This MoU is a testament to our shared commitment to innovation and impact on health. By leveraging our combined expertise, we aim to create scalable and sustainable solutions that will redefine how vaccines and therapies are developed and delivered so everyone, everywhere, can get them.”

Mauricio Zuma, CEO of Bio-Manguinhos, noted: “This joint commitment will develop new products to expand public access to health solutions in Brazil and beyond.”